For instance, Sal reduces drug-induced liver injury (Yuan et al., 2019), guards the liver against ischemia/reperfusion injury (Cai et al., 2017), and eases nonalcoholic fatty liver disease (NAFLD) by AMPK-dependent TXNIP/NLRP3 pathway (Zheng et al., 2018). Here, TXNIP is linked to metabolic dysfunction-associated steatotic liver disease.